Fast Five Quiz: Idiopathic Pulmonary Fibrosis Treatment

Guy W. Soo Hoo, MD, MPH; Zab Mosenifar, MD

Disclosures

May 12, 2022

Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease. Although the cause of IPF is unknown, factors thought to increase an individual's risk of developing IPF include a history of smoking, gastroesophageal reflux disease, environmental exposures, and genetic predispositions.

Patients with IPF present with fatigue, dry cough, and progressive respiratory distress of more than 6 months, with no improvement of symptoms despite treatment with antibiotics and corticosteroids. The clinical course of IPF is complicated and the prognosis is poor, with a median survival of 3-5 years from diagnosis.

Early diagnosis of IPF and initiation of treatment are essential to improve patient outcomes. The 2018 updated clinical practice guidelines for IPF by the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society include recommendations to facilitate early diagnosis and provide guidance on treatment.

How much do you know about IPF treatment? Test your knowledge with this quick quiz.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....